Market Overview

UPDATE: Jefferies Reiterates Hold Rating, Raises PT on ResMed

Share:
Related RMD
Leader In The 'Growing' Sleep-Disordered Breathing Market Might Be Worth An Investment
Morning Market Losers
ResMed revenues up 9% in FQ4 (Seeking Alpha)

In a report published Friday, Jefferies reiterated its Hold rating on ResMed (NYSE: RMD), and raised its price target from $35.00 to $42.00.

Jefferies noted, “RMD reported strong FQ2 results with revs and EPS beating by $13mm and $0.02. The upside was across the board, albeit off favorable year ago comps. Although we have clearly missed the ride, the tailwinds of HST & cardio adoption coupled with margin benefits from mix and Shanghai manufacturing are still blowing. That said, the stock is fully valued and Round II implementation in the US remains a hard to handicap risk keeping us at Hold.”

ResMed closed on Thursday at $45.47.

Latest Ratings for RMD

DateFirmActionFromTo
Jul 2015Morgan StanleyUpgradesEqual-weightOverweight
Jun 2015BarclaysInitiates Coverage onEqual-weight
Apr 2015Goldman SachsDowngradesBuyNeutral

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (RMD)

Get Benzinga's Newsletters